Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
633
mi
from 98109
Santa Rosa, CA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
633
mi
from 98109
Santa Rosa, CA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from 98109
Washington, D.C.,
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from 98109
Washington, D.C.,
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2720
mi
from 98109
Hollywood, FL
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2720
mi
from 98109
Hollywood, FL
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2202
mi
from 98109
Columbus, GA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2202
mi
from 98109
Columbus, GA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
1721
mi
from 98109
Hinsdale, IL
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
1721
mi
from 98109
Hinsdale, IL
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
1848
mi
from 98109
Lansing, MI
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
1848
mi
from 98109
Lansing, MI
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
1920
mi
from 98109
Southfield, MI
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
1920
mi
from 98109
Southfield, MI
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2067
mi
from 98109
Hattiesburg, MS
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2067
mi
from 98109
Hattiesburg, MS
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
mi
from 98109
St. Louis, MT
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
mi
from 98109
St. Louis, MT
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2161
mi
from 98109
Rochester, NY
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2337
mi
from 98109
Chapel Hill, NC
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2368
mi
from 98109
Abington, PA
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2368
mi
from 98109
Abington, PA
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2226
mi
from 98109
Greenville, SC
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2226
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
2090
mi
from 98109
Chattanooga, TN
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
2090
mi
from 98109
Chattanooga, TN
Click here to add this to my saved trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated:  6/8/2017
GSK Investigational Site
440
mi
from 98109
Calgary,
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Status: Enrolling
Updated: 6/8/2017
GSK Investigational Site
440
mi
from 98109
Calgary,
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Duke University
2341
mi
from 98109
Durham, NC
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Duke University
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
University of Chicago
1737
mi
from 98109
Chicago, IL
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
University of Chicago
1737
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
West Virginia University
2160
mi
from 98109
Morgantown, WV
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
West Virginia University
2160
mi
from 98109
Morgantown, WV
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
H. Lee Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Emory University
2178
mi
from 98109
Atlanta, GA
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Emory University
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated:  6/13/2017
Washington University
1716
mi
from 98109
Saint Louis, MO
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Enrolling
Updated: 6/13/2017
Washington University
1716
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
984
mi
from 98109
Orange, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1504
mi
from 98109
Westwood, KA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1504
mi
from 98109
Westwood, KA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2400
mi
from 98109
New York, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
2321
mi
from 98109
Washington, D.C.,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
2321
mi
from 98109
Washington, D.C.,
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
509
1811
mi
from 98109
Graz,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
509
1811
mi
from 98109
Graz,
Click here to add this to my saved trials
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/14/2017
Paoli Memorial Hospital
2355
mi
from 98109
Paoli, PA
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/14/2017
Paoli Memorial Hospital
2355
mi
from 98109
Paoli, PA
Click here to add this to my saved trials
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/14/2017
Fox Chase Cancer Center
2373
mi
from 98109
Philadelphia, PA
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/14/2017
Fox Chase Cancer Center
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1733
mi
from 98109
Chicago, IL
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
Status: Enrolling
Updated:  6/15/2017
West County Plastic Surgeons of Washington University
1706
mi
from 98109
Saint Louis, MO
Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction
Status: Enrolling
Updated: 6/15/2017
West County Plastic Surgeons of Washington University
1706
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/15/2017
University of Pittsbutgh Cancer Institute
2135
mi
from 98109
Pittsburgh, PA
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/15/2017
University of Pittsbutgh Cancer Institute
2135
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Markey Cancer Center
2005
mi
from 98109
Lexington, KY
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Markey Cancer Center
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Ohio State University
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Penn State University
2220
mi
from 98109
University Park, PA
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Penn State University
2220
mi
from 98109
University Park, PA
Click here to add this to my saved trials